Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus

Nikolina Mihaylova, Silviya Bradyanova, Petroslav Chipinski, Melinda Herbáth, Stela Chausheva, Dobroslav Kyurkchiev, J. Prechl, Andrey I. Tchorbanov

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is a polygenic pathological disorder which involves multiple organs. Self-specific B cells play a main role in the lupus pathogenesis by generating autoantibodies as well as by serving as important autoantigen-presenting cells. Autoreactive T lymphocytes, on the other hand, are responsible for B cell activation and proliferation, and cytokine production. Therefore, both factors promote the idea that a down-modulation of activated self-reactive T and B cells involved in the pathogenic immune response is a reasonable approach for SLE therapy. Annexin A1 (ANX A1) is expressed by many cell types and binds to phospholipids in a Ca2+ dependent manner. Abnormal expression of ANX A1 was found on activated B and T cells in both murine and human autoimmunity, suggesting its potential role as a therapeutic target. While its role on T lymphocytes is through formyl peptide receptor-like molecules (FPRL), and the formed ANX A1/FPRL pathway modulates T cell receptor signalling, there is still no fool-proof data available for the role of ANX A1 in B cells. We employed a lupus model of Balb/c mice with pristane-induced SLE which very closely resembles human lupus. In the present study, we investigated the possibility to modulate the autoimmune response in a pristane-induced mouse model of SLE using an anti- ANX A1 antibody. Administration of this monoclonal antibody resulted in the inhibition of T-cell activation and proliferation, suppression of IgG anti-dsDNA antibody-secreting plasma cells and of proteinuria, decreased disease activity and prolonged survival compared to control group.

Original languageEnglish
Pages (from-to)1-12
Number of pages12
JournalAutoimmunity
DOIs
Publication statusAccepted/In press - Mar 15 2017

Fingerprint

Annexin A1
Systemic Lupus Erythematosus
B-Lymphocytes
T-Lymphocytes
Formyl Peptide Receptor
Autoimmunity
Cell Proliferation
Antibody-Producing Cells
Autoantigens
T-Cell Antigen Receptor
Plasma Cells
Proteinuria
Autoantibodies
Anti-Idiotypic Antibodies
Phospholipids
Immunoglobulin G
Monoclonal Antibodies
pristane
Cytokines
Control Groups

Keywords

  • Anti-annexin A1 antibody
  • Balb/c mice
  • Pristane-induced systemic lupus erythematosus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Mihaylova, N., Bradyanova, S., Chipinski, P., Herbáth, M., Chausheva, S., Kyurkchiev, D., ... Tchorbanov, A. I. (Accepted/In press). Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. Autoimmunity, 1-12. https://doi.org/10.1080/08916934.2017.1300884

Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. / Mihaylova, Nikolina; Bradyanova, Silviya; Chipinski, Petroslav; Herbáth, Melinda; Chausheva, Stela; Kyurkchiev, Dobroslav; Prechl, J.; Tchorbanov, Andrey I.

In: Autoimmunity, 15.03.2017, p. 1-12.

Research output: Contribution to journalArticle

Mihaylova, N, Bradyanova, S, Chipinski, P, Herbáth, M, Chausheva, S, Kyurkchiev, D, Prechl, J & Tchorbanov, AI 2017, 'Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus', Autoimmunity, pp. 1-12. https://doi.org/10.1080/08916934.2017.1300884
Mihaylova N, Bradyanova S, Chipinski P, Herbáth M, Chausheva S, Kyurkchiev D et al. Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. Autoimmunity. 2017 Mar 15;1-12. https://doi.org/10.1080/08916934.2017.1300884
Mihaylova, Nikolina ; Bradyanova, Silviya ; Chipinski, Petroslav ; Herbáth, Melinda ; Chausheva, Stela ; Kyurkchiev, Dobroslav ; Prechl, J. ; Tchorbanov, Andrey I. / Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus. In: Autoimmunity. 2017 ; pp. 1-12.
@article{18be70b410e548c4ae6e8c3ee4454ee7,
title = "Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus",
abstract = "Systemic lupus erythematosus (SLE) is a polygenic pathological disorder which involves multiple organs. Self-specific B cells play a main role in the lupus pathogenesis by generating autoantibodies as well as by serving as important autoantigen-presenting cells. Autoreactive T lymphocytes, on the other hand, are responsible for B cell activation and proliferation, and cytokine production. Therefore, both factors promote the idea that a down-modulation of activated self-reactive T and B cells involved in the pathogenic immune response is a reasonable approach for SLE therapy. Annexin A1 (ANX A1) is expressed by many cell types and binds to phospholipids in a Ca2+ dependent manner. Abnormal expression of ANX A1 was found on activated B and T cells in both murine and human autoimmunity, suggesting its potential role as a therapeutic target. While its role on T lymphocytes is through formyl peptide receptor-like molecules (FPRL), and the formed ANX A1/FPRL pathway modulates T cell receptor signalling, there is still no fool-proof data available for the role of ANX A1 in B cells. We employed a lupus model of Balb/c mice with pristane-induced SLE which very closely resembles human lupus. In the present study, we investigated the possibility to modulate the autoimmune response in a pristane-induced mouse model of SLE using an anti- ANX A1 antibody. Administration of this monoclonal antibody resulted in the inhibition of T-cell activation and proliferation, suppression of IgG anti-dsDNA antibody-secreting plasma cells and of proteinuria, decreased disease activity and prolonged survival compared to control group.",
keywords = "Anti-annexin A1 antibody, Balb/c mice, Pristane-induced systemic lupus erythematosus",
author = "Nikolina Mihaylova and Silviya Bradyanova and Petroslav Chipinski and Melinda Herb{\'a}th and Stela Chausheva and Dobroslav Kyurkchiev and J. Prechl and Tchorbanov, {Andrey I.}",
year = "2017",
month = "3",
day = "15",
doi = "10.1080/08916934.2017.1300884",
language = "English",
pages = "1--12",
journal = "Autoimmunity",
issn = "0891-6934",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Annexin A1 as a target for managing murine pristane-induced systemic lupus erythematosus

AU - Mihaylova, Nikolina

AU - Bradyanova, Silviya

AU - Chipinski, Petroslav

AU - Herbáth, Melinda

AU - Chausheva, Stela

AU - Kyurkchiev, Dobroslav

AU - Prechl, J.

AU - Tchorbanov, Andrey I.

PY - 2017/3/15

Y1 - 2017/3/15

N2 - Systemic lupus erythematosus (SLE) is a polygenic pathological disorder which involves multiple organs. Self-specific B cells play a main role in the lupus pathogenesis by generating autoantibodies as well as by serving as important autoantigen-presenting cells. Autoreactive T lymphocytes, on the other hand, are responsible for B cell activation and proliferation, and cytokine production. Therefore, both factors promote the idea that a down-modulation of activated self-reactive T and B cells involved in the pathogenic immune response is a reasonable approach for SLE therapy. Annexin A1 (ANX A1) is expressed by many cell types and binds to phospholipids in a Ca2+ dependent manner. Abnormal expression of ANX A1 was found on activated B and T cells in both murine and human autoimmunity, suggesting its potential role as a therapeutic target. While its role on T lymphocytes is through formyl peptide receptor-like molecules (FPRL), and the formed ANX A1/FPRL pathway modulates T cell receptor signalling, there is still no fool-proof data available for the role of ANX A1 in B cells. We employed a lupus model of Balb/c mice with pristane-induced SLE which very closely resembles human lupus. In the present study, we investigated the possibility to modulate the autoimmune response in a pristane-induced mouse model of SLE using an anti- ANX A1 antibody. Administration of this monoclonal antibody resulted in the inhibition of T-cell activation and proliferation, suppression of IgG anti-dsDNA antibody-secreting plasma cells and of proteinuria, decreased disease activity and prolonged survival compared to control group.

AB - Systemic lupus erythematosus (SLE) is a polygenic pathological disorder which involves multiple organs. Self-specific B cells play a main role in the lupus pathogenesis by generating autoantibodies as well as by serving as important autoantigen-presenting cells. Autoreactive T lymphocytes, on the other hand, are responsible for B cell activation and proliferation, and cytokine production. Therefore, both factors promote the idea that a down-modulation of activated self-reactive T and B cells involved in the pathogenic immune response is a reasonable approach for SLE therapy. Annexin A1 (ANX A1) is expressed by many cell types and binds to phospholipids in a Ca2+ dependent manner. Abnormal expression of ANX A1 was found on activated B and T cells in both murine and human autoimmunity, suggesting its potential role as a therapeutic target. While its role on T lymphocytes is through formyl peptide receptor-like molecules (FPRL), and the formed ANX A1/FPRL pathway modulates T cell receptor signalling, there is still no fool-proof data available for the role of ANX A1 in B cells. We employed a lupus model of Balb/c mice with pristane-induced SLE which very closely resembles human lupus. In the present study, we investigated the possibility to modulate the autoimmune response in a pristane-induced mouse model of SLE using an anti- ANX A1 antibody. Administration of this monoclonal antibody resulted in the inhibition of T-cell activation and proliferation, suppression of IgG anti-dsDNA antibody-secreting plasma cells and of proteinuria, decreased disease activity and prolonged survival compared to control group.

KW - Anti-annexin A1 antibody

KW - Balb/c mice

KW - Pristane-induced systemic lupus erythematosus

UR - http://www.scopus.com/inward/record.url?scp=85015648900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015648900&partnerID=8YFLogxK

U2 - 10.1080/08916934.2017.1300884

DO - 10.1080/08916934.2017.1300884

M3 - Article

SP - 1

EP - 12

JO - Autoimmunity

JF - Autoimmunity

SN - 0891-6934

ER -